Lexeo Therapeutics, Inc. (LXEO)
(Delayed Data from NSDQ)
$17.45 USD
+0.26 (1.51%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $17.43 -0.02 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LXEO 17.45 +0.26(1.51%)
Will LXEO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for LXEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXEO
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
LXEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LXEO
Analysts Conflicted on These Healthcare Names: Equillium (EQ), Lexeo Therapeutics, Inc. (LXEO) and Teladoc (TDOC)
Buy Rating on Lexeo Therapeutics: Promising Gene Therapy Innovations and Strategic Approvals Ahead
Lexeo Therapeutics initiated with bullish view at H.C. Wainwright, here's why
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Krystal Biotech (KRYS) and Veeva Systems (VEEV)
Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed